drugset / Trial / NCT03611010

Dose-ranging Efficacy and Pharmacokinetics Study of Intravenous Atorvastatin in Hypercholesterolemic Patients

NCT03611010

Phase 2 Completed 40 enrolled Cumberland Pharmaceuticals
Non-randomizedSequentialOpen-labelTreatment

Summary

Open-label study will titrate doses of intravenous atorvastatin and monitor respective LDL-C levels in hypercholesterolemic patients previously controlled on oral atorvastatin.

Timeline

Start
2018-08-07
Primary completion
2020-02-17
Completion
2020-02-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule Intravenous

Indications